Nurix Therapeutics shares are trading higher after its deal with Seagen to develop a portfolio of degrader-antibody conjugates.
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics has entered into a deal with Seagen to develop a portfolio of degrader-antibody conjugates. This has led to an increase in Nurix's share prices.
September 07, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nurix Therapeutics' shares have increased following the announcement of a partnership with Seagen.
The partnership with Seagen to develop a portfolio of degrader-antibody conjugates is a positive development for Nurix Therapeutics. This has led to an increase in investor confidence, reflected in the rise in share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Seagen has entered into a partnership with Nurix Therapeutics to develop a portfolio of degrader-antibody conjugates.
While the partnership with Nurix Therapeutics is a positive development for Seagen, the news does not directly mention any impact on Seagen's share prices. Therefore, the short-term impact on Seagen's stock is neutral.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80